Zevra Therapeutics (ZVRA) Other Gross PP&E Adjustments (2018 - 2025)
Zevra Therapeutics (ZVRA) has disclosed Other Gross PP&E Adjustments for 9 consecutive years, with -$6.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 85.89% year-over-year to -$6.8 million, compared with a TTM value of -$6.8 million through Dec 2025, down 85.89%, and an annual FY2025 reading of -$6.8 million, down 85.89% over the prior year.
- Other Gross PP&E Adjustments was -$6.8 million for Q4 2025 at Zevra Therapeutics, down from -$1.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $1.4 million in Q4 2021 and bottomed at -$7.1 million in Q2 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$2.4 million, with a median of -$1.2 million recorded in 2021.
- The sharpest move saw Other Gross PP&E Adjustments skyrocketed 150.25% in 2021, then tumbled 785.55% in 2024.
- Year by year, Other Gross PP&E Adjustments stood at $1.4 million in 2021, then plummeted by 308.37% to -$2.9 million in 2022, then increased by 0.1% to -$2.9 million in 2023, then decreased by 24.0% to -$3.6 million in 2024, then tumbled by 85.89% to -$6.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ZVRA at -$6.8 million in Q4 2025, -$1.7 million in Q3 2025, and -$2.1 million in Q2 2025.